SCHEMBL25311809

SCHEMBL25311809

CC(C)(C)OC(=O)CCOCCCOCCCOCCCO

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.40
▸ CYP4F2 P78329 1/20 0.39
▸ CYP4A11 Q02928 1/20 0.39
▸ GAA P10253 1/20 0.36
▸ HDAC1 Q13547 2/20 0.34
▸ HDAC2 Q92769 2/20 0.34
▸ HDAC6 Q9UBN7 2/20 0.34
▸ HDAC3 O15379 1/20 0.34
▸ HDAC8 Q9BY41 1/20 0.34
▸ TSHR P16473 1/20 0.33
▸ STING1 Q86WV6 1/20 0.33
▸ EPHX2 P34913 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ THRB P10828 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21634225 0.98 TDP1 (0.41) TDP1CYP4F2CYP4A11GAAHDAC1
SCHEMBL26118545 0.93 CYP4F2 (0.46) TDP1CYP4F2CYP4A11GAAHDAC1
SCHEMBL22326306 0.91 GAA (0.46) TDP1CYP4F2CYP4A11GAAHDAC1
SCHEMBL26504855 0.91 GAA (0.46) TDP1CYP4F2CYP4A11GAAHDAC1
SCHEMBL21068491 0.91 GAA (0.46) TDP1CYP4F2CYP4A11GAAHDAC1
SCHEMBL23970511 0.91 TDP1 (0.41) TDP1CYP4F2CYP4A11GAAHDAC1
SCHEMBL29132578 0.89 GAA (0.43) TDP1CYP4F2CYP4A11GAAHDAC1
SCHEMBL898476 0.86 TSHR (0.42) TDP1CYP4F2CYP4A11HDAC1HDAC2
SCHEMBL20325479 0.85 TSHR (0.42) TSHRMEN1THRBHTTKMT2A
SCHEMBL26740073 0.85 TSHR (0.42) TSHRMEN1THRBHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 — — US disclosed
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 — — US disclosed
EP-4214189-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL Business Ltd (GB) 2023-07-26 — — EP disclosed
WO-2022058733-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS PLC (GB) 2022-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS TTR, C1R, APOB TDP1 3163/4885CYP4F2 1044/4885CYP4A11 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback